期刊文献+

艾塞那肽对新诊断2型糖尿病患者生化指标及骨代谢的影响 被引量:1

下载PDF
导出
摘要 目的:分析艾塞那肽对新诊断2型糖尿病患者生化指标及骨代谢的影响。方法:选取2013年1月-2014年12月在我院就诊的2型糖尿病患者40人进行基本生化指标的检查后,皮下注射艾塞那肽进行治疗24周后,测定生化指标,比较治疗前后各项指标的变化情况及患者腰椎的骨密度。结果:与治疗前相比,治疗24周后,患者的空腹血糖值(FPG)、糖化血红蛋白(Hb A1c)、总脂肪率显著降低,差异具有统计学意义(P<0.01);胰岛素抵抗指数(HOMA-IR)、体重、身体质量指数(BMI)值及脂肪指数(FMI)值显著降低,差异统计学意义(P<0.05);胰岛素功能指数(HOMA-β)、骨钙蛋白(OC)、环磷酰胺(CTX)、抗酒石酸5b(TRAc P5b)、骨密度(BMD)值与治疗前相比,差异无统计学意义(P>0.05)。结论:使用艾塞那肽治疗2型糖尿病患者的血糖值和机体对胰岛素抵抗作用得到良好的改善,但患者的骨密度及骨转化物标志物等并无明显变化。
作者 欧阳文
出处 《深圳中西医结合杂志》 2015年第15期149-150,共2页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献7

二级参考文献37

  • 1Buse JB,Henry RR,Han J,et al.Effects of exenatide on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes[J].Diabetes Care,2004,27(11):2628-2635.
  • 2Kendall DM,RiddleMC,Rosenstock J,et al.Effects of exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J].Diabetes Care,2005,28(5):1083-1091.
  • 3Defronzo RA,Ratner RE,Han J,et al.Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes[J].Diabetes Care,2005,28 (5):1092-1100.
  • 4Blonde L,Klein EJ,Han J,et al.Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J].Diabetes Obes Metab,2006,8(4):436-447.
  • 5Klonoff DC,Buse JB,Nielsen LL,et al.Exenatide effects on diabetes,obesity,cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Curr Med Res Opin,2008,24(1):275-286.
  • 6Yoon NM,Cavaghan MK,Brunelle RL,et al.Exenatide added to insulin therapy:a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting[J].Clin Ther,2009,31(7):1511-1523.
  • 7Sheffield CA,Kane MP,Busch RS,et al.Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus[J].Endocr Pract,2008,14(3):285-292.
  • 8Nayak UA,Govindan J,Baskar V,et al.Exenatide therapy in insulin-treated type 2 diabetes and obesity[J].QJM,2010,103(9):687-694.
  • 9American Diabetes Association.Standards of medical care in diabetes-2011[J].Diabetes Care,2011,34(Suppl 1):S11-S61.
  • 10Davies MJ,Donnelly R,Barnett AH,et al.Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes:results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin(HEELA)study[J].Diabetes Obes Metab,2009,11(12):1153-1162.

共引文献43

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部